CO2018003756A2 - Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida - Google Patents

Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida

Info

Publication number
CO2018003756A2
CO2018003756A2 CONC2018/0003756A CO2018003756A CO2018003756A2 CO 2018003756 A2 CO2018003756 A2 CO 2018003756A2 CO 2018003756 A CO2018003756 A CO 2018003756A CO 2018003756 A2 CO2018003756 A2 CO 2018003756A2
Authority
CO
Colombia
Prior art keywords
carboxyamide
pyrazolo
pyrimidin
ether derivatives
cyclic ether
Prior art date
Application number
CONC2018/0003756A
Other languages
English (en)
Inventor
Christoph Hoenke
Barbara Bertani
Marco Ferrara
Giacomo Fossati
Sara Frattini
Riccardo Giovannini
Scott Hobson
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2018003756A2 publication Critical patent/CO2018003756A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a derivados de éter espirocíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida de la Fórmula general (I) que son inhibidores de la fosfodiesterasa 2, útiles en el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. Además, la invención se refiere a procesos para preparar composiciones farmacéuticas, así como a procesos para la fabricación de compuestos de acuerdo con la invención.
CONC2018/0003756A 2015-10-13 2018-04-09 Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida CO2018003756A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189600.8A EP3156405A1 (en) 2015-10-13 2015-10-13 Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
PCT/EP2016/074380 WO2017064082A1 (en) 2015-10-13 2016-10-12 Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

Publications (1)

Publication Number Publication Date
CO2018003756A2 true CO2018003756A2 (es) 2018-07-10

Family

ID=54293164

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003756A CO2018003756A2 (es) 2015-10-13 2018-04-09 Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida

Country Status (30)

Country Link
US (5) US10023575B2 (es)
EP (2) EP3156405A1 (es)
JP (1) JP6626965B2 (es)
KR (1) KR102611558B1 (es)
CN (2) CN108137602B (es)
AU (1) AU2016338602B2 (es)
BR (1) BR112018004347B1 (es)
CA (1) CA3001929C (es)
CL (1) CL2018000856A1 (es)
CO (1) CO2018003756A2 (es)
DK (1) DK3362453T3 (es)
EA (1) EA035350B1 (es)
ES (1) ES2912223T3 (es)
HK (1) HK1254651A1 (es)
HR (1) HRP20220595T1 (es)
IL (1) IL258070B (es)
LT (1) LT3362453T (es)
MA (1) MA42988B1 (es)
MX (1) MX2018004524A (es)
MY (1) MY195169A (es)
NZ (1) NZ740119A (es)
PE (2) PE20181447A1 (es)
PH (1) PH12018500796A1 (es)
PL (1) PL3362453T3 (es)
PT (1) PT3362453T (es)
RS (1) RS63218B1 (es)
SA (1) SA518391334B1 (es)
SI (1) SI3362453T1 (es)
UA (1) UA124576C2 (es)
WO (1) WO2017064082A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156405A1 (en) * 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
RU2671964C1 (ru) * 2017-08-30 2018-11-08 Сиа Эволед Пиразоло[1,5-а]пиримидинкарбоксилаты гадолиния и органические светодиоды на их основе
CN112867722B (zh) * 2019-01-18 2022-09-23 苏州亚盛药业有限公司 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers)
CN110339197A (zh) * 2019-06-24 2019-10-18 中山大学 一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
EP1572113B1 (en) * 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
AP2006003632A0 (en) 2003-12-16 2006-06-30 Pfizer Prod Inc Pyridol[2,3-D] pyrimidine-2,4-Diamines as PDE 2 inhibitors
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
ATE471324T1 (de) 2004-09-02 2010-07-15 Nycomed Gmbh Triazolophthalazine
JP5130053B2 (ja) 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
CN101103033B (zh) 2005-01-05 2010-08-04 尼科梅德有限责任公司 作为pde2抑制剂的***并酞嗪
BRPI0502411A (pt) 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
JP4847275B2 (ja) 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
BRPI0617659A2 (pt) * 2005-10-21 2011-08-02 Mitsubishi Tanabe Pharma Corp composto de pirazolo[1,5-a]pirimidina e composição farmacêutica que o contém
WO2007121319A2 (en) 2006-04-14 2007-10-25 University Of California Compostions and methods for determining and predicting treatment responses for depression and anxiety
TWI419889B (zh) * 2006-07-05 2013-12-21 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
PE20131197A1 (es) * 2008-10-31 2013-11-06 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
JP2014526453A (ja) 2011-09-09 2014-10-06 ハー・ルンドベック・アクチエゼルスカベット ピリジン化合物およびそれらの使用
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
EP3061754A4 (en) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
EP3156405A1 (en) * 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
JP2017095366A (ja) * 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体

Also Published As

Publication number Publication date
LT3362453T (lt) 2022-05-25
EP3362453A1 (en) 2018-08-22
EA201890922A1 (ru) 2018-11-30
EA035350B1 (ru) 2020-05-29
IL258070A (en) 2018-05-31
PE20190778A1 (es) 2019-06-06
JP6626965B2 (ja) 2019-12-25
CL2018000856A1 (es) 2018-07-27
HRP20220595T1 (hr) 2022-06-10
MA42988B1 (fr) 2022-04-29
AU2016338602B2 (en) 2020-07-16
CA3001929A1 (en) 2017-04-20
JP2018534279A (ja) 2018-11-22
US10479794B2 (en) 2019-11-19
CN108137602A (zh) 2018-06-08
MX2018004524A (es) 2018-06-27
US20170101411A1 (en) 2017-04-13
BR112018004347A2 (pt) 2018-10-09
CN108137602B (zh) 2021-09-28
KR20180063316A (ko) 2018-06-11
SI3362453T1 (sl) 2022-06-30
BR112018004347B1 (pt) 2023-12-05
PH12018500796A1 (en) 2018-10-29
SA518391334B1 (ar) 2021-03-29
PE20181447A1 (es) 2018-09-12
PL3362453T3 (pl) 2022-07-25
EP3156405A1 (en) 2017-04-19
WO2017064082A1 (en) 2017-04-20
DK3362453T3 (da) 2022-06-07
RS63218B1 (sr) 2022-06-30
KR102611558B1 (ko) 2023-12-11
ES2912223T3 (es) 2022-05-25
MA42988A (fr) 2021-04-07
US20200039991A1 (en) 2020-02-06
US20180134720A1 (en) 2018-05-17
US20210032259A1 (en) 2021-02-04
AU2016338602A1 (en) 2018-03-15
IL258070B (en) 2020-06-30
US20230286993A1 (en) 2023-09-14
CA3001929C (en) 2023-11-28
MY195169A (en) 2023-01-11
HK1254651A1 (zh) 2019-07-26
CN114181213A (zh) 2022-03-15
PT3362453T (pt) 2022-05-04
NZ740119A (en) 2022-02-25
US11691977B2 (en) 2023-07-04
UA124576C2 (uk) 2021-10-13
US10875867B2 (en) 2020-12-29
US10023575B2 (en) 2018-07-17
EP3362453B1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
CO2017011851A2 (es) Compuestos novedosos
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CR20150633A (es) Derivados del bipirazol como inhibidores jak
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
CO2018003756A2 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2018001085A1 (es) Derivados de indolin-2-ona
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ